title: The Yin and the Yang of CV risks in patients with diabetes.
authors.forename: Surabhi
authors.initials: S
authors.lastname: Dangi-Garimella
mesh_terms: D000218:Adamantane / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000209:etiology*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy; D004151:Dipeptides / Q000009:adverse effects / Q000627:therapeutic use; D064420:Drug-Related Side Effects and Adverse Reactions; D006333:Heart Failure / Q000139:chemically induced / Q000209:etiology; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000150:complications*; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use; D054795:Incretins / Q000009:adverse effects / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000139:chemically induced / Q000209:etiology; D000077205:Pioglitazone; D018570:Risk Assessment; D000077154:Rosiglitazone; D056737:Safety-Based Drug Withdrawals; D020521:Stroke / Q000139:chemically induced / Q000209:etiology; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000592:standards / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D004151:Dipeptides; D007004:Hypoglycemic Agents; D054795:Incretins; D045162:Thiazolidinediones; D000077154:Rosiglitazone; C502994:saxagliptin; D000218:Adamantane; D000077205:Pioglitazone